Gensight Biologics SA - Asset Resilience Ratio

Latest as of June 2022: 59.58%

Gensight Biologics SA (SIGHT) has an Asset Resilience Ratio of 59.58% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Gensight Biologics SA PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€24.15 Million

≈ $28.23 Million USD Cash + Short-term Investments

Total Assets

€40.52 Million

≈ $47.38 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2021)

This chart shows how Gensight Biologics SA's Asset Resilience Ratio has changed over time. See net asset quality index of Gensight Biologics SA to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Gensight Biologics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SIGHT stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€24.15 Million	59.58%
Short-term Investments	€0.00	0%
Total Liquid Assets	€24.15 Million	59.58%

Asset Resilience Insights

Very High Liquidity: Gensight Biologics SA maintains exceptional liquid asset reserves at 59.58% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Gensight Biologics SA Industry Peers by Asset Resilience Ratio

Compare Gensight Biologics SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hugel Inc KQ:145020	Biotechnology	29.57%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Absci Corp NASDAQ:ABSI	Biotechnology	59.86%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%

Annual Asset Resilience Ratio for Gensight Biologics SA (2014–2021)

The table below shows the annual Asset Resilience Ratio data for Gensight Biologics SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	78.18%	€44.29 Million ≈ $51.78 Million	€56.65 Million ≈ $66.23 Million	-1.93pp
2020-12-31	80.11%	€37.94 Million ≈ $44.36 Million	€47.36 Million ≈ $55.37 Million	+20.85pp
2019-12-31	59.26%	€19.25 Million ≈ $22.51 Million	€32.48 Million ≈ $37.98 Million	-11.70pp
2018-12-31	70.96%	€26.24 Million ≈ $30.68 Million	€36.98 Million ≈ $43.23 Million	-18.17pp
2017-12-31	89.13%	€55.45 Million ≈ $64.82 Million	€62.21 Million ≈ $72.73 Million	-2.01pp
2016-12-31	91.14%	€53.98 Million ≈ $63.11 Million	€59.23 Million ≈ $69.25 Million	+81.68pp
2014-12-31	9.46%	€1.40 Million ≈ $1.64 Million	€14.82 Million ≈ $17.32 Million	--

pp = percentage points

About Gensight Biologics SA

PA:SIGHT France Biotechnology

Market Cap

$23.49 Million

€20.09 Million EUR

Market Cap Rank

#25251 Global

#411 in France

Share Price

€0.09

Change (1 day)

+1.54%

52-Week Range

€0.08 - €0.21

All Time High

€9.58